Menu
1-702-720-6310 info@microcapspecualtors.com

5 Biotech Stocks to Watch

Biotech stocks have been making investors major profits for years. Recently, the stem cell market has started to heat up again.  

One stock leading that push has been BioRestorative Therapies, Inc. (BRTX).  The stock has been receiving increased attention by the street.  If this is your first time hearing about BRTX make sure you start doing your own due diligence immediately.  As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar of most investors, which presents a great opportunity to investors that are currently in the know on BRTX.  And the company just had very important, as well as favorable news which could lead to even more developments for the company.  Keep BRTX on your radar because missing out on this very innovative and interesting company would be very disappointing.

BRTX as well as these other biotechs could be big for your portfolio’s heath: BioRestorative Therapies, Inc. (BRTX), Geron Corporation (GERN), Insys Therapeutics, Inc. (INSY), GT Biopharma, Inc. (GTBP), and Cara Therapeutics, Inc. (CARA).

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $13.22M Share Price: $1.80

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Journal of Translational Medicine has published the results of the Company’s study evaluating the benefits of long-term hypoxic (low oxygen) culturing of human bone marrow-derived mesenchymal stem cells (cells used in the Company’s product, BRTX-100). The study included data on cell fitness and whole genome expression and discussed its implication on cellular therapies targeting intervertebral discs and its microenvironment.

The FDA has authorized BioRestorative to commence a Phase 2 clinical trial using hypoxic cultured bone marrow-derived mesenchymal stem cells in its lead candidate, BRTX-100, to treat chronic lower back pain.

Geron Corporation, Inc. (GERN)

Market Cap: $1.09B Share Price: $5.96

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.  On the company’s recent earnings conference call, CEO Scarlett began by handing off to CFO Bloom. She reported on Geron’s net loss for the quarter of $6.9 million in contrast to the comparable quarter in 2017 loss of $6.4 million. Geron’s Q2, 2018 net reflects $3.2 million of research and development expenses for its share of costs under the collaboration agreement together with $4.2 million of general and administrative expenses.

Insys Therapeutics, Inc. (INSY)

Market Cap: $687.50M Share Price: $9.26

Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys’ treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. Despite the news the stock has maintained investor interest. Investors believe the company will bounce back.

GT Biopharma, Inc. (GTBP)

Market Cap: $2.03B Share Price: $8.67

GT Biopharma, Inc. (GTBP)  announced that it has appointed David Cardino, CPA, MBA as Vice President of Finance. Most recently, Mr. Cardino led the finance and accounting operations of Agensys, Inc., a U.S. based oncology research center of Astellas Pharma, Inc., with a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies directed at a variety of cancer indications, with annual expenses and capital investment in excess of $100M.

Cara Therapeutics, Inc. (CARA)

Market Cap: $786.59M Share Price: $20.02

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and fifteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX.  BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

Search